Quarterly ResultAug 11, 2026, 07:06 AM
Neuraxis Q2 Revenue +116% to $1.9M; Gross Margin 85.9%
AI Summary
NeurAxis, Inc. reported strong second quarter 2026 results, with revenue increasing 116% year-over-year to $1.9 million, driven by the effective Category I CPT code for PENFS. Gross margin expanded to 85.9%, and cash used in operations decreased. The company also achieved significant operational milestones, including securing a VA Federal Supply Schedule contract and expanding FDA clearance for its IB-Stim technology, positioning it for continued growth and broader insurance coverage.
Key Highlights
- Revenue increased 116% year-over-year to $1.9 million in Q2 2026.
- Gross margin expanded to 85.9% in Q2 2026 from 83.6% in Q2 2025.
- Cash balance was $8.3 million as of June 30, 2026.
- Cash used in operations decreased to $1.0 million in Q2 2026 from $1.5 million in Q2 2025.
- Unit deliveries increased 60% year-over-year in Q2 2026.
- Category I CPT code for PENFS became effective January 1, 2026, increasing payer coverage.
- Awarded a Veterans Affairs Federal Supply Schedule (FSS) contract.
- Received FDA clearance for abdominal pain in functional dyspepsia (FD) for patients 8+.
Price Impact
More from NRXS